Obviously, it would be of great interest to study whether assessment of in vitro GC sensitivity, as measured by the IL2, GILZ, and whole cell dexamethasone-binding assays, correlates with in vivo response to GC therapy in BD. This evidence concerns the gene IL2 and Behcet disease.